In February, the abstract from the ARRIVE trial — a multi-center randomized controlled trial comparing induction of labor at 39 weeks gestation with expectant management of labor in first-time mothers —was presented at the annual Society for Maternal-Fetal Medicine (SMFM) conference in Dallas, Texas.
The findings presented indicate that cesarean birth rates were lower in the induction group (18.6%) than the expectant management group (22.2%) without causing a statistically significant increase in adverse perinatal outcomes. However, WSHA’s Safe Deliveries Roadmap encourages all our member hospitals to continue to promote the current labor management guidelines (ACOG, SMFM, BREE collaborative & Safe Deliveries Roadmap: Labor Bundle).
We encourage continuing to follow these recommendations until the ARRIVE trial has been formally published and reviewed for its strengths, limitations and clinical implications.
Selected partner responses to the ARRIVE trial:
- The American College of Obstetricians and Gynecologists (ACOG)
- The Society for Maternal-Fetal Medicine (SMFM) response
- The California Maternal Quality Care Collaborative (CMQCC) response